Evidence mapPaperPMID 36189281Full record

ReviewFrontiers in immunology2022

Melatonin pretreatment on exosomes: Heterogeneity, therapeutic effects, and usage.

Zilan Zhou, Ruiping Wang, Jie Wang, Yujia Hao, Qingpeng Xie, Lu Wang, Xing Wang

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors.Medical oncology (Northwood, London, England) · 2024
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zilan ZhouSchool and Hospital of Stomatology, Shanxi Medical University, Taiyuan, China.
Ruiping WangScience and Technology Information and Strategy Research Center of Shanxi, Taiyuan, China.
Jie WangSchool and Hospital of Stomatology, Shanxi Medical University, Taiyuan, China.
Yujia HaoSchool and Hospital of Stomatology, Shanxi Medical University, Taiyuan, China.
Qingpeng XieSchool and Hospital of Stomatology, Shanxi Medical University, Taiyuan, China.
Lu WangSchool and Hospital of Stomatology, Shanxi Medical University, Taiyuan, China.
Xing WangSchool and Hospital of Stomatology, Shanxi Medical University, Taiyuan, China.
Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic outcomes of exosome-based therapies have greatly exceeded initial expectations in many clinically intractable diseases due to the safety, low toxicity, and immunogenicity of exosomes, but the production of the exosomes is a bottleneck for wide use. To increase the yield of the exosomes, various solutions have been tried, such as hypoxia, extracellular acidic pH, etc. With a limited number of cells or exosomes, an alternative approach has been developed to improve the efficacy of exosomes through cell pretreatment recently. Melatonin is synthesized from tryptophan and secreted in the pineal gland, presenting a protective effect in pathological conditions. As a new pretreatment method, melatonin can effectively enhance the antioxidant, anti-inflammatory, and anti-apoptotic function of exosomes in chronic kidney disease, diabetic wound healing, and ischemia-reperfusion treatments. However, the current use of melatonin pretreatment varies widely. Here, we discuss the effects of melatonin pretreatment on the heterogeneity of exosomes based on the role of melatonin and further speculate on the possible mechanisms. Finally, the therapeutic use of exosomes and the usage of melatonin pretreatment are described.

Indexed as

ExosomesMelatoninAnti-Inflammatory AgentsAntioxidantsTryptophanAnti-Inflammatory AgentsAntioxidantsMelatoninTryptophanexosomesheterogeneitymelatoninpretreatmenttherapeutic

Identifiers

PMID36189281
PMCPMC9524263
OpenAlexW4296175739

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.